Global Chronic Idiopathic Constipation (CIC) Drugs Market is estimated to grow at CAGR of 6.43% during the forecast period of 2017-2025.The global CIC drugs market is dominated by lubiprostone drugs with more than 40% market share in 2014.
Browse the full report Chronic Idiopathic Constipation (CIC) Drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016–2022 at http://www.credenceresearch.com/report/chronic-idiopathic-constipation-cic-drugs-market
Geographically the CIC drugs market is segmented into regional market of the North America (U.S. and Canada), Asia Pacific (China, Japan and rest of the APAC), and Europe (U.K. and Germany and rest of the Europe).
The CIC drugs market is growing rapidly in the North America and Asia Pacific. The North America CIC drugs market is expected to grow at CAGR of 7.20% with an expected rise of US $818 Mn in 2016 and market is worth optimize up to US $1527.50 Mn by 2025. The North America accounted for the largest revenue share in 2016; where about 28% of North American population is suffering from CIC disorder.
The Asia Pacific CIC drugs market is anticipated grow at CAGR of 5.76% during the forecast period of 2017-2025 and the revenue generated by the CIC drugs sales is expected to rise from US $303.4 Mn in 2016 and about to reach at US $5024 Mn by 2025.
The global CIC drugs market is studied for lubiprostone, linaclotide and other drugs .However lubiprostone and linaclotide are the two main drugs for CIC treatment, where linaclotide has become the most popular drug in this market. The sale of lubiprostone drug will go under sharp decline due to its lesser efficacy and patent loss. Recently the U.S. Food and Drug Administration approved Trulance (Plecanatide) drug for the treatment of CIC in adults. The CIC drugs market is growing rapidly in the region of North America.
The leading players in the CIC drugs market are Synergy Pharmaceuticals, Cosmo Pharmaceuticals SA, Daiichi Sankyo Co Ltd., Bayer AG, Actavis, Roche Holding Ag, Sucampo Pharmaceuticals Inc., Ironwood, Valeant Pharmaceutical, Theravance Biopharma Inc, and others.
The CIC drugs market look promising for the upcoming years, these are emerging as an alternative for the surgical treatments. However lack of awareness about disease, ignoring proper medication and easy availability of generic drugs without prescription may hamper the market growth.
Excessive intake of CIC drugs causes gas problem, diarrhea, weak immunity, stomach cramps and possible risk of cancer or other diseases. Fiber products such as psyllium (Metamuail), polycarbophil (Fibercon) and methyl ceclulose (Citrucel) are the best choice for treating constipation.
The global chronic idiopathic constipation drugs market is moderately competitive and is characterized by a large demand for over the counter medications. Considering CIC as a symptom and not a disorder, there is a greater tendency of patients towards opting for self-medication through OTC drugs.
Constipation is never considered as a disease but a syndrome or a side effect; people are less likely to visit doctors to get prescription for constipation. Thus, the CIC drugs market is dominated by over the counter prescription with over 50% market share in 2014.The OTC drugs market will continue to dominate the market growing at the highest CAGR during the forecast period of 2017-2025.